Diffusion Pharmaceuticals (NASDAQ:DFFN) announced its earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.07), Bloomberg Earnings reports.
Shares of NASDAQ DFFN opened at $0.33 on Friday. The company has a market cap of $16.72 million, a PE ratio of -0.29 and a beta of -1.43. Diffusion Pharmaceuticals has a 1-year low of $0.31 and a 1-year high of $2.08.
DFFN has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $1.25 target price on shares of Diffusion Pharmaceuticals in a research note on Monday, August 20th. ValuEngine upgraded Diffusion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Featured Article: Quiet Period
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.